Home > Publications database > Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies > print

001     296121
005     20250403112515.0
024 7 _ |2 doi
|a 10.3390/cancers16244251
037 _ _ |a DKFZ-2025-00051
082 _ _ |a 610
100 1 _ |0 P:(DE-HGF)0
|a Gonçalves, Márcia
|b 0
|e First author
245 _ _ |a Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies
260 _ _ |a Basel
|b MDPI
|c 2024
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1736258137_26416
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
500 _ _ |a #EA:D120#EA:D121#LA:D120#LA:D121#
536 _ _ |0 G:(DE-HGF)POF4-314
|a 314 - Immunologie und Krebs (POF4-314)
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |0 P:(DE-He78)ae4deeee80cae8c94cc144333ae4cc5a
|a Warwas, Karsten
|b 1
700 1 _ |0 P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a
|a Meyer, Marten
|b 2
|u dkfz
700 1 _ |0 P:(DE-He78)fd29481ff828e64dd1002b7a4efc5932
|a Schwartz-Albiez, Reinhard
|b 3
700 1 _ |0 P:(DE-He78)8a8d6fb28cd77106b895bffdaa346dcd
|a Bulbuc, Nadja
|b 4
700 1 _ |a Zörnig, Inka
|b 5
700 1 _ |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
|a Jäger, Dirk
|b 6
|u dkfz
700 1 _ |0 P:(DE-He78)b2290261145f21c46f2d42783c69d104
|a Momburg, Frank
|b 7
|e Last author
|u dkfz
773 _ _ |0 PERI:(DE-600)2527080-1
|a 10.3390/cancers16244251
|g Vol. 16, no. 24, p. 4251 -
|n 24
|p 4251
|t Cancers
|v 16
|x 2072-6694
|y 2024
909 C O |o oai:inrepo02.dkfz.de:296121
|p VDB
|p OpenAPC
|p openCost
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-HGF)0
|a Deutsches Krebsforschungszentrum
|b 0
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)ae4deeee80cae8c94cc144333ae4cc5a
|a Deutsches Krebsforschungszentrum
|b 1
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a
|a Deutsches Krebsforschungszentrum
|b 2
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)fd29481ff828e64dd1002b7a4efc5932
|a Deutsches Krebsforschungszentrum
|b 3
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)8a8d6fb28cd77106b895bffdaa346dcd
|a Deutsches Krebsforschungszentrum
|b 4
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
|a Deutsches Krebsforschungszentrum
|b 6
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)b2290261145f21c46f2d42783c69d104
|a Deutsches Krebsforschungszentrum
|b 7
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-314
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2023-07-31T16:07:06Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2023-07-31T16:07:06Z
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2023-10-26
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2023-10-26
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DOAJ Journal
|2 APC
|0 PC:(DE-HGF)0003
920 2 _ |0 I:(DE-He78)D120-20160331
|k D120
|l Angewandte Tumor-Immunität
|x 0
920 2 _ |0 I:(DE-He78)D121-20160331
|k D121
|l AG Antigenpräsentation und T/NK-Zell-Akt
|x 1
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l Angewandte Tumor-Immunität
|x 0
920 1 _ |0 I:(DE-He78)D121-20160331
|k D121
|l AG Antigenpräsentation und T/NK-Zell-Akt
|x 1
920 0 _ |0 I:(DE-He78)D120-20160331
|k D120
|l Angewandte Tumor-Immunität
|x 0
920 0 _ |0 I:(DE-He78)D121-20160331
|k D121
|l AG Antigenpräsentation und T/NK-Zell-Akt
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a I:(DE-He78)D121-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21